Review
Cell Biology
Sarah Saxena, Veronique Kruys, Raf De Jongh, Joseph Vamecq, Mervyn Maze
Summary: Aseptic surgical trauma induces the release of HMGB1, triggering the immune response and resulting in postoperative cognitive decline.
Article
Biochemistry & Molecular Biology
Wataru Takaki, Hirotaka Konishi, Daiki Matsubara, Katsutoshi Shoda, Tomohiro Arita, Satoshi Kataoka, Jun Shibamoto, Hirotaka Furuke, Kazuya Takabatake, Hiroki Shimizu, Shuhei Komatsu, Atsushi Shiozaki, Takeshi Kubota, Kazuma Okamoto, Eigo Otsuji
Summary: This study reveals that extracellular HMGB1 promotes the progression and metastasis of gastric cancer, and plasma HMGB1 concentrations can serve as a prognostic marker in gastric cancer patients. Recombinant human soluble thrombomodulin (rTM) targeting HMGB1 shows potential therapeutic effects in gastric cancer treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cell Biology
Bram DeWulf, Laurens Minsart, Franck Verdonk, Veronique Kruys, Michael Piagnerelli, Mervyn Maze, Sarah Saxena
Summary: Targeting HMGB1 can be a strategy to reduce sepsis-induced encephalopathy and complement non-pharmacological interventions.
Article
Gastroenterology & Hepatology
Zhuolun Song, Hui Han, Xiaodong Ge, Sukanta Das, Romain Desert, Dipti Athavale, Wei Chen, Sai Santosh Babu Komakula, Daniel Lantvit, Natalia Nieto
Summary: This study investigated the protective role of intracellular neutrophil-derived HMGB1 in early allograft dysfunction after liver transplantation. The results showed that the absence of Hmgb1 in recipient myeloid cells exacerbated graft injury. Therefore, intracellular HMGB1 plays an important role in protecting against early graft injury after liver transplantation.
Article
Biochemistry & Molecular Biology
Takaaki Totoki, Takashi Ito, Shingo Yamada, Goichi Honda, Tsuyoshi Hattori, Ikuro Maruyama
Summary: In this study, a monoclonal antibody specific to desHMGB1 was obtained and used to detect desHMGB1 through ELISA. The results showed a significant increase in plasma desHMGB1 levels in septic mice treated with rTM. This suggests that using the novel monoclonal antibody for ELISA may aid in the in-depth analysis of HMGB1-induced pathogenicity and rTM therapeutic efficiency.
MOLECULAR MEDICINE
(2021)
Article
Biochemistry & Molecular Biology
Fabian Essig, Lilith Babilon, Christoph Vollmuth, Alexander M. Kollikowski, Mirko Pham, Laszlo Solymosi, Karl Georg Haeusler, Peter Kraft, Guido Stoll, Michael K. Schuhmann
Summary: The study demonstrated that HMGB1 is a significant component of thromboemboli causing large vessel occlusion stroke, with its expression strongly correlated with the number of neutrophils and platelets in the thrombus. Additionally, HMGB1 was found to colocalize with neutrophils and NETs and be spatially close to platelets in the thrombus.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Cardiac & Cardiovascular Systems
Federico Biscetti, Giovanni Tinelli, Maria Margherita Rando, Elisabetta Nardella, Andrea Leonardo Cecchini, Flavia Angelini, Giuseppe Straface, Marco Filipponi, Vincenzo Arena, Dario Pitocco, Antonio Gasbarrini, Massimo Massetti, Andrea Flex
Summary: The study found that HMGB1 is an independent risk factor for carotid plaque vulnerability in diabetic patients, with higher levels of HMGB1 and inflammatory cytokines in ICAS patients compared to WICAS patients. Among ICAS patients, those with unstable plaque had even higher levels of these cytokines. HMGB1 and osteoprotegerin were independently associated with unstable plaque in ICAS patients.
CARDIOVASCULAR DIABETOLOGY
(2021)
Review
Pharmacology & Pharmacy
Ryuichi Tsujita, Maho Tsubota, Fumiko Sekiguchi, Atsufumi Kawabata
Summary: HMGB1, a nuclear protein, promotes pain signals and inflammation after being released to the extracellular space. Endogenous HMGB1 accumulated in neurons, perineuronal cells, or immune cells participates in various forms of pain. TM and TMα can reduce HMGB1 degradation, preventing and reversing different types of pathological pain.
BRITISH JOURNAL OF PHARMACOLOGY
(2021)
Article
Clinical Neurology
Sina Hemmer, Sebastian Senger, Christoph J. Griessenauer, Andreas Simgen, Joachim Oertel, Juergen Geisel, Philipp Hendrix
Summary: The study investigated the role of HMGB1 in aneurysmal subarachnoid hemorrhage and found that admission HMGB1 levels were an independent predictor for delayed cerebral ischemia. Initial insult burden and radiological vasospasm were correlated with HMGB1 levels, but serial HMGB1 levels were not associated with cerebral ischemia, functional outcome, or radiological vasospasm.
NEUROSURGICAL REVIEW
(2022)
Article
Biochemistry & Molecular Biology
Ilijana Grigorov, Snezana Pejic, Ana Todorovic, Dunja Drakulic, Filip Veljkovic, Jadranka Miletic Vukajlovic, Katarina Bobic, Ivan Soldatovic, Sinisa Durasevic, Nebojsa Jasnic, Sanja Stankovic, Sofija Glumac, Violeta Mihailovic-Vucinic, Branislava Milenkovic
Summary: Careful monitoring of mild/moderate COVID-19 patients is crucial due to the rapid progression of complications. This study identified HMGB1 and HO-1 as potential biomarkers for COVID-19 management, based on their serum concentrations at hospital admission. The increase in HO-1 may provide protection against oxidative stress and inflammation, while the level of HMGB1 reflects the activity of the innate immune system.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Immunology
Hayder M. Al-kuraishy, Ali I. Al-Gareeb, Luay Alkazmi, Ola A. Habotta, Gaber El-Saber Batiha
Summary: HMGB1 is a multifunctional nuclear protein that plays a critical role in the inflammatory signaling pathway. Elevated levels of HMGB1 in COVID-19 patients are associated with disease severity and complications. Targeting the HMGB1 pathway may be beneficial in reducing the severity of the disease.
INFLAMMOPHARMACOLOGY
(2022)
Article
Clinical Neurology
Wanying Shan, Liang Xu, Zhuoyin Qiu, Jingwen Wang, Jiaxing Shao, Jie Feng, Jie Zhao
Summary: This study aimed to investigate whether high-mobility group box 1 (HMGB1) levels could predict post-stroke depression (PSD) at 3 months after acute ischemic stroke. The results demonstrated that higher HMGB1 levels in the acute phase of ischemic stroke were associated with an increased risk of PSD, with an optimal cutoff point of 8.6 ng/mL showing good sensitivity and specificity for predicting PSD.
NEUROLOGICAL SCIENCES
(2022)
Article
Immunology
Anette Teo Hansen Selno, Stephanie Schlichtner, Inna M. Yasinska, Svetlana S. Sakhnevych, Walter Fiedler, Jasmin Wellbrock, Steffen M. Berger, Elena Klenova, Bernhard F. Gibbs, Elizaveta Fasler-Kan, Vadim V. Sumbayev
Summary: HMGB1, a non-histone protein, is released by stressed, dying, or dead cells into the extracellular matrix, potentially impacting cancer cells' ability to evade immune surveillance. Through recognition as a ligand, TLR4 mediates the induction of TGF-beta by HMGB1, leading to the expression of the immunosuppressive protein galectin-9 in cancer cells.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Tuo Tang, Shengnan Wang, Tianyu Cai, Zhenyu Cheng, Yu Meng, Shimei Qi, Yao Zhang, Zhilin Qi
Summary: This study found that HMGB1 promotes proliferation and migration of gastric cancer cells through the RAGE-mediated signaling pathways, involving multiple molecular mechanisms. It highlights HMGB1 as a potential therapeutic target for GC, providing important evidence for future research and treatment strategies.
Article
Immunology
Jie Zhao, Fang Xu, Wanying Xu, Rong Lv, Juan Wang, Xufeng Yang
Summary: This study found an association between elevated HMGB1 levels and the severity of white matter lesions (WMLs) in stroke patients, particularly in the periventricular region.
JOURNAL OF INFLAMMATION RESEARCH
(2023)